GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List

Explanation to Bollinger's Bands

Bollinger Bands was created by John Bollinger in the early 1980s, its purpose is to define price action relative to the assets highs and lows. This technical indicator is used to identify buy and sell signals and has proven very well in doing so.

Bollinger Bands consist of a set of three curves drawn in relation to securities prices. The middle band is a measure of the intermediate-term trend, usually a simple moving average, that serves as the base for the upper and lower bands. The interval between the upper and lower bands and the middle band is determined by volatility, typically the standard deviation of the same data that were used for the average. StockInvest.us uses Bollingers suggested 20 day average.

Middle Bollinger Band = 20-period simple moving average
Upper Bollinger Band = Middle Bollinger Band + 2 * 20-period standard deviation
Lower Bollinger Band = Middle Bollinger Band - 2 * 20-period standard deviation

BandWidth defines the current width of the band.
%b defines the current position within the band.

BandWidth = (Upper Bollinger Band - Lower Bollinger Band) / Middle Bollinger Band
%b = (Last - Lower Bollinger Band) / (Upper Bollinger Band - Lower Bollinger Band)

Live Samples:

Bollinger Bottleneck Buy Pattern 1
Bollinger Bottleneck Buy Pattern 2
Bollinger Bottleneck Sell Pattern

Bottlenecks in bandwidth indicate an upcoming change. Break up through the moving average line or continuous movements above the moving average line indicate a break up, and vice versa.

Source: http://www.bollingerbands.com

RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of URGN
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Friday for UroGen Pharma Ltd stock after losing 3.72%
(Updated on Apr 19, 2024)

Sell candidate since Apr 15, 2024 Loss -9.07% PDF

The UroGen Pharma Ltd stock price fell by -3.72% on the last day (Friday, 19th Apr 2024) from $14.26 to $13.73. During the last trading day the stock fluctuated 8.43% from a day low at $13.17 to a day high of $14.28. The price has fallen in 5 of the last 10 days but is still up by 0.96% over the past 2 weeks. Volume has increased on the last day by 72 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 381 thousand shares were bought and sold for approximately $5.23 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -16.95% during the next 3 months and, with a 90% probability hold a price between $10.43 and $14.06 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

URGN Signals & Forecast

A buy signal was issued from a pivot bottom point on Wednesday, April 10, 2024, and so far it has risen 6.02%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development. The UroGen Pharma Ltd stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $14.31 and $15.29. A break-up above any of these levels will issue buy signals. Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for UroGen Pharma Ltd stock

UroGen Pharma Ltd finds support from accumulated volume at $13.64 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.11 between high and low, or 8.43%. For the last week, the stock has had daily average volatility of 6.40%.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (URGN) For The Upcoming Trading Day Of Monday 22nd

For the upcoming trading day on Monday, 22nd we expect UroGen Pharma Ltd to open at $13.73, and during the day (based on 14 day Average True Range), to move between $12.71 and $14.75, which gives a possible trading interval of +/-$1.02 (+/-7.45%) up or down from last closing price. If UroGen Pharma Ltd takes out the full calculated possible swing range there will be an estimated 14.91% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $13.64 (0.66%) than the resistance at $15.10 (9.98%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is UroGen Pharma Ltd stock A Buy?

UroGen Pharma Ltd holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -2.881 Sell Candidate Unchanged

Predicted Opening Price for UroGen Pharma Ltd of Monday, April 22, 2024

Fair opening price April 22, 2024 Current price
$13.73 ( 0.0243%) $13.73

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for URGN

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 14.84 8.06 %
R2 14.41 4.97 %
R1 14.15 3.06 %
Current price: 13.73
Support S1 13.30 -3.11 %
S2 13.04 -5.02 %
S3 12.62 -8.11 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 16.66 21.34 %
R2 15.76 14.79 %
R1 15.10 9.98 %
Current price 13.73
Support S1 13.64 -0.655%
S2 13.25 -3.50%
S3 12.95 -5.68%

FAQ

What is the symbol for UroGen Pharma Ltd Stock and on which exchange is it traded?
The symbol for UroGen Pharma Ltd is URGN and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell UroGen Pharma Ltd Stock?
UroGen Pharma Ltd holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy UroGen Pharma Ltd Stock?
UroGen Pharma Ltd Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy UroGen Pharma Ltd Stock.

What's the current price of UroGen Pharma Ltd Stock?
As of the end of day on the 2024-04-19, the price of an UroGen Pharma Ltd (URGN) share was $13.73.

What is the 52-week high and low for UroGen Pharma Ltd Stock?
The 52-week high for UroGen Pharma Ltd Stock is $24.13 and the 52-week low is $8.69.

What is the market capitalization of UroGen Pharma Ltd Stock?
As of the 2024-04-19, the market capitalization of UroGen Pharma Ltd is 485.899M.

When is the next earnings date for UroGen Pharma Ltd?
The upcoming earnings date for UroGen Pharma Ltd is May 09, 2024.
Click to get the best stock tips daily for free!

About UroGen Pharma Ltd

UroGen Pharma Ltd UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms... URGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT